Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beth A Hellerstedt

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
CA: a Cancer Journal for Clinicians|May 23, 2002
The current state of hormonal therapy for prostate cancerBeth A Hellerstedt, Kenneth J Pienta
Current Opinion in Oncology|May 1, 2002
Testicular cancerBeth A Hellerstedt, Kenneth J Pienta
Urologic Oncology|September 5, 2003
The truth is out there: an overall perspective on androgen deprivationBeth A Hellerstedt, Kenneth J Pienta
Current Opinion in Oncology|June 5, 2003
Germ cell tumors: review of selected studies from 2002Beth A Hellerstedt, Kenneth J Pienta
The American Journal of the Medical Sciences|March 3, 2010
Postsplenectomy cytomegalovirus mononucleosis is a distinct clinicopathologic syndromeXiang Y Han, Beth A Hellerstedt, Charles A Koller
Clinical Prostate Cancer|March 30, 2004
Antimetastatic drugs in prostate cancerChristopher H Chay, Carlton C Cooper, Beth A Hellerstedt, et al.
Clinical Lung Cancer|December 12, 2018
Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung CarcinomaBeth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With LetrozoleLea K Krekow, Beth A Hellerstedt, Rufus P Collea, et al.
Cancer Medicine|March 28, 2018
Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancerFrankie Ann Holmes, Beth A Hellerstedt, John E Pippen, et al.
Clinical Genitourinary Cancer|December 12, 2012
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancerMatthew D Galsky, Noah M Hahn, Thomas Powles, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
CA: a Cancer Journal for Clinicians|May 23, 2002
The current state of hormonal therapy for prostate cancerBeth A Hellerstedt, Kenneth J Pienta
Current Opinion in Oncology|May 1, 2002
Testicular cancerBeth A Hellerstedt, Kenneth J Pienta
Urologic Oncology|September 5, 2003
The truth is out there: an overall perspective on androgen deprivationBeth A Hellerstedt, Kenneth J Pienta
Current Opinion in Oncology|June 5, 2003
Germ cell tumors: review of selected studies from 2002Beth A Hellerstedt, Kenneth J Pienta
The American Journal of the Medical Sciences|March 3, 2010
Postsplenectomy cytomegalovirus mononucleosis is a distinct clinicopathologic syndromeXiang Y Han, Beth A Hellerstedt, Charles A Koller
Clinical Prostate Cancer|March 30, 2004
Antimetastatic drugs in prostate cancerChristopher H Chay, Carlton C Cooper, Beth A Hellerstedt, et al.
Clinical Lung Cancer|December 12, 2018
Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung CarcinomaBeth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With LetrozoleLea K Krekow, Beth A Hellerstedt, Rufus P Collea, et al.
Cancer Medicine|March 28, 2018
Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancerFrankie Ann Holmes, Beth A Hellerstedt, John E Pippen, et al.
Clinical Genitourinary Cancer|December 12, 2012
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancerMatthew D Galsky, Noah M Hahn, Thomas Powles, et al.
Pageof 1